Deyaa Adib, M.D. has over 28 years of experience in the biotechnology and pharmaceutical industries in multidisciplinary oncology and immuno-oncology from drug research, through commercialization experience with 7 global registrations including Taxotere, Eloxatin, Xtandi, Oncaspar, Tazverick, Onivyde and Eclusig in multiple indications across hematologic malignancies and solid tumors. Currently serving as the Chief Medical Officer at AffyImmune advancing a CAR-T cell therapy program towards registration in anaplastic thyroid cancer via successful FDA interactions and financing rounds.
Previously, he served as SVP & Chief Medical Officer at FibroGen (NASDAQ FGEN) leading the development of late stage 1st in class mAB (CTGF) and an ADC (CD46) in pancreatic cancer and prostate cancer indications and previously the CMO for Triumvira Immunologics leading the development of early and mid stage TCR (TAC-T) autologous cell therapies for multiple targets in GI solid tumors and securing multiple financing rounds. Dr. Adib served as Acting CMO at Rain Therapeutics advancing the organization from the private into public sector via licensing deals leading to a successful IPO.
Before that, he was the Vice President of late-stage development at Blueprint Medicines advancing the devleopment of avaprinitnib towards registration in GIST. Dr. Adib also served as Global Therapeutics Head for solid tumors at Baxalta building the oncology portfolio from the ground up and advancing the development of nano-liposomal irinotecan towards approval in pancreatic cancer, pegasparage in ALL and securing multiple licensing/M&A opportunities in the I-O space leading to the acquisition by Shire for 11.2 Billion for the oncology portfolio. He also served as Head of Hematologic Malignancies at ARIAD Pharmaceuticals repositioning ponatinib & brigatinib from local into global domain hence, securing the acquisition by Takeda for 5.2 Billion . Earlier in his career, he held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma. Dr. Adib obtained an M.B., B.Ch. (M.D.) degree from Cairo University School of Medicine in Cairo, Egypt. He completed his postgraduate medical oncology training at the Anglo-American Cancer Institute in Cairo and at Tufts University School of Medicine, Boston, MA, in clinical pharmacology, drug development and regulation. He completed his research fellowship in cancer immunology at St. Joseph’s Hospital & Medical Center in Paterson, New Jersey.